Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The tendency within the weekly time frame is positive above the technical support level at 135.98 USD
Weaknesses
  • The group usually releases earnings worse than estimated.
  • The company's enterprise value to sales, at 4.81 times its current sales, is high.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
JOHNSON & JOHNSON-0.08%383 760
ROCHE HOLDING AG0.67%296 096
PFIZER, INC.-1.79%213 750
MERCK & CO., INC.-11.78%202 534
NOVARTIS AG-17.88%182 470
ABBVIE INC.7.19%167 264
NOVO NORDISK A/S7.82%154 231
ASTRAZENECA PLC12.13%147 070
AMGEN INC.1.49%143 302
ELI LILLY AND COMPANY14.35%136 233
BRISTOL-MYERS SQUIBB COMPAN..-8.62%132 729
SANOFI-1.19%131 610
GLAXOSMITHKLINE PLC-14.01%100 031
CHUGAI PHARMACEUTICAL CO., ..45.92%73 669
JIANGSU HENGRUI MEDICINE CO..29.41%71 499
BAYER AG-22.76%65 363
More Results
Financials (USD)
Sales 2020 80 530 M - -
Net income 2020 17 416 M - -
Net Debt 2020 3 827 M - -
P/E ratio 2020 22,3x
Yield 2020 2,76%
Capitalization 384 B 384 B -
EV / Sales 2020 4,81x
EV / Sales 2021 4,33x
Nbr of Employees 132 200
Free-Float 84,3%
Upcoming event on JOHNSON & JOHNSON
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes